This study is currently not recruiting new participants. Add it to your favourites and check back later.
Clinical Trial

Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Study Description

Psoriasis Longitudinal Assessment and Registry (PSOLAR)

The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque psoriasis, and other all forms of psoriasis (such as plaque psoriasis and psoriatic arthritis occurring together). The registry study will track the behavior of the disease in response to other therapies, such as other biologic drugs. The registry will also evaluate clinical outcomes; disease characteristics, including physician reported assessment of psoriatic arthritis (PsA); quality of life, and potential risks for patients who may receive standard therapies for psoriasis.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Biological - Ustekinumab

Ustekinumab will be administered as prescribed by physician.

Biological - Biological therapies other than infliximab, ustekinumab and guselkumab

Biological therapies will be administered as prescribed by physician.

Drug - Conventional systemic agents

Conventional systemic agents will be administered as prescribed by physician.

Biological - Infliximab

Infliximab will be administered as prescribed by physician.

Biological - Guselkumab

Guselkumab will be administered as prescribed by physician.

Additional Information

Official Study Title

A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics

Clinical Trial ID

NCT00508547

ParticipAid ID

PdR6qd